ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q3Scopus Q2SCImago #10,164Hybrid

Biomarkers in Medicine

Abbreviation (ISO):BIOMARKERS MED
•
Identifier (ISSN):1752-0363(Print)/1752-0371(Online)
•
Publisher:Future Medicine Ltd.
Clarivate IF (2026)
2.1– 0
Journal Impact Factor
IF Trend↓
WoS Quartile
Q3
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Biomarkers in Medicine

WoS Q3
12342.3520182.2720192.4820202.8520212.520222.220231.920242.120252.12026
Annual Impact Factor Metric
Current (2026):2.1
Scopus SJR & RankScopus Q2
0.582
#10,164

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
62

62 papers with at least that number of citations each

WoS: SCIE / JCRQ3
Self-Citation Rate5.3%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
155articles/year
4.08% Gold OA•79.12% Original Research

Aims & Scope

Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.

Topics Covered (Recognized by AI)
Medicine99.7%Biology88.6%Internal medicine87.8%Genetics72.7%Chemistry67.4%Biochemistry65.5%Pathology56.9%Biomarker34.1%Gene30%Oncology29.9%Psychology29.2%Immunology28.1%Endocrinology27.8%Cancer27.2%Surgery25.5%Bioinformatics24.9%Psychiatry24.8%Disease23.6%Mathematics22.9%

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

MEDICINE, RESEARCH & EXPERIMENTAL

Q3
Rank121/191
IndexSCIE
JCISCIE2026

MEDICINE, RESEARCH & EXPERIMENTAL

Q3
Rank112/191
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF2.1
Articles / Year75
Total Citations22
2025
IF2.1
Articles / Year143
Total Citations228
2024
IF1.9
Articles / Year115
Total Citations468
2023
IF2.2
Articles / Year94
Total Citations539
2022
IF2.498
Articles / Year133
Total Citations971

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #10,164Scopus Q2SCImago Profile
Scopus Coverage:2008-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q2
0.582

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
1.99

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$2,939 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations677
3-Year Documents315
Citable Documents307

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate40.1%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Biochemistry (medical)Q2
Drug DiscoveryQ2
Clinical BiochemistryQ3
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 5.3%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
4区 (Zone 4)Medicine
Minor Category (Specific Field):
4区MEDICINE, RESEARCH & EXPERIMENTAL
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Biomarkers in Medicine (abbr: BIOMARKERS MED, ISSN: 1752-0363) is a peer-reviewed international scholarly journal in the field of Medicine, published by Future Medicine Ltd. in England since 2007. The periodical holds a Journal Impact Factor (JIF) of 2.10, ranking in quartile Q3 of Web of Science (SCIE), a Scopus SJR indicator of 0.582 (Q2), an H-index of 62.

The journal enforces rigorous peer evaluation with a publication frequency of Bimonthly, an annual output of approximately 155 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $2,939 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Future Medicine Ltd.
Publication Language
English
Frequency
Bimonthly
Founding Year
2007
Indexing & Databases
SCIEScopusPubMed
Editorial Address
FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: d9d25d08-3a69-4ea0-b38a-147ff85fae11
Database Updated: 2026-10-01